NASDAQ:TENX • US88032L6056
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TENAX THERAPEUTICS INC (TENX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-17 | Cantor Fitzgerald | Initiate | Overweight |
| 2026-03-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-17 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-08 | Piper Sandler | Initiate | Overweight |
| 2025-08-14 | Guggenheim | Maintains | Buy -> Buy |
| 2024-10-24 | Leerink Partners | Initiate | Outperform |
| 2024-10-14 | Guggenheim | Initiate | Buy |
| 2024-09-30 | William Blair | Initiate | Outperform |
| 2024-02-20 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-11-13 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-03-07 | Roth MKM | Initiate | Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 375.55% | N/A 110.71% | N/A 65.34% | N/A 58.07% | N/A 41.97% | ||||||||||||
| EBITDA YoY % growth | -10.394M | -19.367M -86.32% | -9.192M 52.54% | -6.884M 25.11% | -8.55M -24.20% | -9.864M -15.36% | -32.724M -231.76% | -11.048M 66.24% | -8.226M 25.54% | -19.494M -136.97% | N/A -25.91% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.426M | -19.386M -85.94% | -9.206M 52.51% | -6.893M 25.12% | -8.555M -24.11% | -9.868M -15.34% | -32.728M -231.66% | -11.053M 66.23% | -8.234M 25.50% | -19.494M -136.75% | -56.385M -189.24% | N/A -58.42% | N/A -10.74% | N/A 22.21% | N/A 127.89% | N/A 386.88% | N/A 119.03% | N/A 25.11% | N/A 87.02% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -12,160.00 | -10,032.00 17.50% | N/A 32.41% | -2,160.00 68.15% | -2,224.00 -2.96% | -3,088.00 -38.85% | N/A 75.40% | -35.38 95.34% | -5.32 84.96% | -1.33 75.00% | N/A -19.64% | N/A 6.28% | N/A 27.09% | N/A 84.05% | N/A 590.18% | N/A 177.21% | N/A 28.79% | N/A 107.23% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.41 -45.71% | -0.42 -54.89% | -0.63 -58.10% | -0.38 1.22% | -0.39 3.75% | -0.39 6.10% | -0.40 37.10% | -0.40 -7.34% | -0.39 1.30% | -0.44 -11.69% | -0.49 -23.08% | -0.56 -39.24% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.116M -68.60% | -22.192M -88.20% | -23.626M -40.58% | -22.576M -37.25% | -20.203M -5.69% | -20.459M 7.81% | -20.365M 13.80% | -20.322M 9.98% | N/A | N/A | N/A | N/A |
All data in USD
12 analysts have analysed TENX and the average price target is 29.33 USD. This implies a price increase of 103.29% is expected in the next year compared to the current price of 14.425.
TENAX THERAPEUTICS INC (TENX) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of TENAX THERAPEUTICS INC (TENX) is -0.41 USD and the consensus revenue estimate is 0 USD.